Project

Randomized phase II study to investigate the efficacy, safety and tolerability of ZK 230211 (25 mg vs. 100 mg) as second-line endocrine therapy for postmenopausal women with hormonereceptor-positive metastatic breast cancer

Completed · 2008 until 2009

Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed
Start Date
2008
End Date
2009
Financing
Industry
Study Design
Prospective, randomized, open-label, parallel group, multi-center
Keywords
hormone receptor-positive tumors, breast cancer
Partner
Prof. Walter Jonat, Kiel, Klinik für Gynäkologie und Geburtshilfe Dr. Iris Kuss Bayer Schering Pharma AG, Study Team Lead, Dr. Michael, Bayer Schering Pharma AG, Dr. Kretschmann Bayer Schering Pharma AG
Brief description/objective

Breast cancer is the second leading cause of cancer-related death in women today (after lung cancer) and is the most common cancer among women worldwide. According to the World Health Organization (WHO), more than 1.2 million people will be diagnosed with breast cancer worldwide in 2005 (Imaginis 2005).
The risk of developing breast cancer increases with age with about two thirds of breast cancers occurring in postmenopausal women. Endocrine therapy is the most important systemic treatment for patients with hormone receptor-positive tumors, which account for two thirds of
breast cancers.